Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to 400.59%.

  • Autolus Therapeutics' EBITDA Margin changed N/A to 400.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 447.55%, marking a year-over-year increase of 19022600.0%. This contributed to the annual value of 2182.25% for FY2024, which is 95066200.0% up from last year.
  • According to the latest figures from Q3 2025, Autolus Therapeutics' EBITDA Margin is 400.59%.
  • Over the past 5 years, Autolus Therapeutics' EBITDA Margin peaked at 11893.31% during Q1 2021, and registered a low of 192696.55% during Q4 2024.
  • In the last 5 years, Autolus Therapeutics' EBITDA Margin had a median value of 589.51% in 2024 and averaged 18966.25%.
  • In the last 5 years, Autolus Therapeutics' EBITDA Margin tumbled by -387107800bps in 2022 and then soared by 241727300bps in 2023.
  • Autolus Therapeutics' EBITDA Margin (Quarter) stood at 17.14% in 2021, then tumbled by -3015bps to 499.73% in 2022, then plummeted by -2448bps to 12730.54% in 2023, then plummeted by -1414bps to 192696.55% in 2024, then soared by 100bps to 400.59% in 2025.
  • Its last three reported values are 400.59% in Q3 2025, 138.36% for Q2 2025, and 657.9% during Q1 2025.